Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Nov. 11, 2013 | |
Document Information [Line Items] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Trading Symbol | 'CYOE | ' |
Entity Registrant Name | 'CytoCore Inc | ' |
Entity Central Index Key | '0000075439 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 269,530,857 |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEET (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
In Thousands, unless otherwise specified | |||
Current Assets: | ' | ' | |
Cash and cash equivalents | $11 | $39 | [1] |
Accounts receivable | 9 | 134 | [1] |
Prepaid expenses and other current assets | 10 | 10 | [1] |
Total current assets | 30 | 183 | [1] |
Fixed assets, net | 17 | 79 | [1] |
Total assets | 47 | 262 | [1] |
Current Liabilities: | ' | ' | |
Accounts payable | 172 | 681 | [1] |
Accrued payroll costs | 3,156 | 2,705 | [1] |
Advances payable to related parties | 70 | 3,175 | [1] |
Accrued expenses | 500 | 903 | [1] |
Notes payable | 36 | 70 | [1] |
Total current liabilities | 3,934 | 7,534 | [1] |
Stockholders' Deficit: | ' | ' | |
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,355 shares issued and outstanding at September 30, 2013 and December 31, 2012 (Liquidation value of all classes of preferred stock $2,871 at September 30, 2013) | 1,487 | 1,487 | [1] |
Common stock, $0.001 par value; 2,000,000,000 and 500,000,000 shares authorized; 269,530,857 and 78,245,623 shares issued and, issuable at September 30, 2013 and December 31, 2012, respectively | 270 | 78 | [1] |
Additional paid-in-capital | 97,116 | 93,407 | [1] |
Treasury stock: 19,209 shares at September 30, 2013 and December 31, 2012 | -327 | -327 | [1] |
Accumulated deficit | -102,433 | -101,917 | [1] |
Total stockholders’ deficit | -3,887 | -7,272 | [1] |
Total liabilities and stockholders’ deficit | $47 | $262 | [1] |
[1] | Derived from audited information |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
Preferred stock, par value | $0.00 | $0.00 | [1] |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | [1] |
Preferred stock, shares issued | 373,355 | 373,355 | [1] |
Preferred stock, shares outstanding | 373,355 | 373,355 | [1] |
Preferred stock, Liquidation value | $2,871 | ' | |
Common stock, par value | $0.00 | $0.00 | [1] |
Common stock, shares authorized | 2,000,000,000 | 500,000,000 | [1] |
Common Stock, Shares, Issued | 269,530,857 | 78,245,623 | [1] |
Treasury stock, shares | 19,209 | 19,209 | [1] |
[1] | Derived from audited information |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Net revenues | $5 | $61 | $19 | $192 |
Operating expenses | ' | ' | ' | ' |
Cost of revenues | 1 | 39 | 7 | 108 |
Research and development, net of settlement of trade debt of $15,000 for the nine months ended September 30, 2012 | 60 | 82 | 209 | 265 |
Selling, general and administrative, (net of adjustment of trade debt of $374,000, a reduction in accrued franchise tax of $217,000 and benefit from the liquidation of subsidiaries of $149,000 for the nine months ended September 30, 2013 and net of adjustment of trade debt of $490,000 for the nine months ended September 30, 2012) | 275 | -136 | 217 | 649 |
Total operating expenses | 336 | -15 | 433 | 1,022 |
Operating (loss) income | -331 | 76 | -414 | -830 |
Other income (expense) | ' | ' | ' | ' |
Interest expense - related party | -2 | -59 | -96 | -170 |
Interest expense | -2 | -3 | -6 | -9 |
Total other income (expense) | -4 | -62 | -102 | -179 |
Net (loss) income | -335 | 14 | -516 | -1,009 |
Preferred stock dividend | -67 | -67 | -199 | -199 |
Net loss applicable to common stockholders | ($402) | ($53) | ($715) | ($1,208) |
Basic and diluted net loss per common share | $0 | $0 | $0 | ($0.02) |
Basic and diluted weighted average number of common shares outstanding | 268,389,553 | 72,964,624 | 172,711,623 | 70,278,553 |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Research and Development Expense [Member] | ' | ' |
Settlement of trade debt | ' | $15,000 |
Selling, General and Administrative Expenses [Member] | ' | ' |
Reduction in accrued franchise tax | 217,000 | ' |
Gain On Liquidation Of Subsidiary | 149,000 | ' |
Settlement of trade debt | $374,000 | $490,000 |
CONDENSED_CONSOLIDATED_STATEME2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | |
Operating Activities: | ' | ' | |
Net loss | ($516) | ($1,009) | |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | |
Depreciation and amortization | 62 | 171 | |
Common stock issued for compensation | 35 | 30 | |
Reduction in accrual for franchise taxes | -217 | 0 | |
Benefit derived from liquidation of subsidiaries | -149 | 0 | |
Interest expense imputed on related party advances | 96 | 170 | |
Common stock issued for services | 41 | 91 | |
Gain on settlement of trade indebtedness | -374 | 490 | |
Changes in assets and liabilities: | ' | ' | |
Accounts receivable | 125 | -162 | |
Prepaid expenses and other current assets | 1 | -1 | |
Accounts payable | -73 | -997 | |
Accrued expenses | 516 | 609 | |
Net cash used in operating activities | -453 | -608 | |
Investing activities: | ' | ' | |
Net cash used in investing activities | 0 | 0 | |
Financing activities: | ' | ' | |
Proceeds from related parties | 145 | 524 | |
Proceeds from sale of machinery | 0 | 70 | |
Sale of common stock | 280 | 0 | |
Net cash provided by financing activities | 425 | 594 | |
Net increase (decrease) in cash and cash equivalents | -28 | -14 | |
Cash and cash equivalents at the beginning of period | 39 | [1] | 14 |
Cash and cash equivalents at end of period | 11 | 0 | |
Supplemental disclosure of cash flow information: | ' | ' | |
Cash paid for interest | 0 | 0 | |
Cash paid for taxes | 0 | 0 | |
Non-cash transactions during the period for: | ' | ' | |
Common stock issued for director fees payable | 200 | 0 | |
Conversion of related party debt to common stock | 3,250 | 0 | |
Write off of certain payables no longer valid due to the statute of limitations | $0 | $490 | |
[1] | Derived from audited information |
Organization
Organization | 9 Months Ended |
Sep. 30, 2013 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Organization | ' |
Note 1. Organization | |
CytoCore, Inc. was incorporated in Delaware in December 1998. Except where the context otherwise requires, the “Company” refers to CytoCore, Inc. and its subsidiaries and predecessors. | |
Currently, the Company has one product of its own for sale – its SoftPap collector. The Company is developing, and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions®. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), treatment and patient monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. The Company plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung, and breast cancers, among others. Within each of these markets the Company anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations. | |
The Company has also begun marketing and selling a companion product that is designed to detect breast cancer, which is manufactured by a third party. | |
During the nine months ended September 30, 2013, Robert McCullough, our Chief Executive Officer and Chief Financial Officer, converted $3,250,000 of debt owed to him into 162,500,000 shares of restricted, unregistered common stock at a price of $0.02 per share. As a result of this transaction, Mr. McCullough beneficially owns 167,690,706 shares of common stock or 62.22% of our outstanding common stock.. Our officers and directors own an aggregate 198,199,145 shares of common stock or 73.53% of our outstanding common stock. | |
Also, during the nine months ended September 30, 2013, the Company liquidated all of its wholly owned subsidiaries and reported a gain of $149,000 as a result. The subsidiaries were inactive and had no operations during the reporting periods. | |
The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to increase sales of its products, develop new products, and raise additional capital. At September 30, 2013, the Company had $11,000 to fund its operations. | |
If the Company is unable to obtain adequate additional financing or generate sufficient sales revenues, it will be unable to continue its product development efforts and other activities and will be forced to curtail or cease operations. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty. | |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation | ' |
Note 2. Basis of Presentation | |
The financial statements for the periods ended September 30, 2013 and 2012 included herein are unaudited. Such financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2013 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). | |
The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC. | |
The Company does not have any comprehensive income or loss. | |
Fixed_Assets
Fixed Assets | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Fixed Assets | ' | |||||||
Note 3. Fixed Assets | ||||||||
Fixed assets consist of the following: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Furniture and fixtures | $ | 40 | $ | 47 | ||||
Laboratory equipment | 508 | 508 | ||||||
Computer and communications equipment | 261 | 261 | ||||||
Design and tooling | 1,204 | 1,204 | ||||||
2,013 | 2,020 | |||||||
Less accumulated depreciation and amortization | -1,996 | -1,941 | ||||||
Total | $ | 17 | $ | 79 | ||||
For the nine months ended September 30, 2013 and 2012, depreciation expense was $62,000 and $171,000, respectively. The Company did not allocate any of the depreciation expense of the machinery and equipment or the design and tooling into inventory since the Company has suspended manufacturing. This depreciation was included as a selling, general and administrative expense as excess idle time. | ||||||||
Accrued_Expenses
Accrued Expenses | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Accrued expenses | ' | |||||||
Note 4. Accrued Expenses | ||||||||
Accrued expenses include the following: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Accrued interest | $ | 29 | $ | 65 | ||||
Accrued franchise and other taxes | 301 | 484 | ||||||
Accrued compensation | 20 | 190 | ||||||
Other accrued expenses | 150 | 164 | ||||||
Total | $ | 500 | $ | 903 | ||||
Notes_Payable_and_Advancesrela
Notes Payable and Advances-related parties | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Notes Payable and Advances-related parties | ' | |||||||
Note 5. Notes Payable and Advances-related parties | ||||||||
Notes payable to unrelated parties consist of: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(Unaudited) | ||||||||
Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate | 15 | 15 | ||||||
9% per annum, due December 20, 2001. | ||||||||
Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; | 21 | 21 | ||||||
due December 31, 2003; interest rate 8% per annum payable | ||||||||
after December 31, 2003 | ||||||||
Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; | — | 34 | ||||||
Interest rate Canadian Prime plus 6% per annum, due December 27, 1999; | ||||||||
represents a debt of AccuMed | ||||||||
$ | 36 | $ | 70 | |||||
During the nine months ended September 30, 2013, the Company liquidated AccuMed, its wholly owned subsidiary. As a result, the note and accrued interest totaling $73,000 due to Xillex Technologies Corporation was recorded as a reduction in selling, general and administration expense. | ||||||||
The Company has failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above. Such notes require the holder to notify the Company in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. The Company has not received any written declarations of default from holders of its remaining outstanding notes payable. | ||||||||
During the nine months ended September 30, 2013, the Company was advanced $145,000 from a related party. These advances are non-interest bearing and are due on demand. However, using an 8% annual interest rate, the Company has recorded a non-cash interest expense totaling approximately $96,000 on the outstanding balance for the nine months ended September 30, 2013. | ||||||||
Stockholders_Equity_Deficit
Stockholders' Equity (Deficit) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Stockholders' Equity (Deficit) [Abstract] | ' | |||||||
Stockholders' Equity | ' | |||||||
Note 6. Stockholders’ Equity (Deficit) | ||||||||
Common stock Split | ||||||||
During the nine months ended September 30, 2013, the Company’s shareholders approved a one for ten reverse split of our common stock. The reverse split did not become effective because the company did not receive approval from the regulatory authorities. Therefore, the reverse split is not reflected in these financial statements. | ||||||||
Loss per share | ||||||||
A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows: | ||||||||
September 30, | September 30, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Basic and Diluted: | ||||||||
Net loss applicable to common stockholder (in thousands) | $ | -715 | $ | -1,208 | ||||
Weighted average common shares outstanding | 172,711,623 | 70,278,553 | ||||||
Net loss per common share | $ | 0 | $ | -0.02 | ||||
Warrants to purchase 705,667 and 922,667 common shares and preferred stock convertible into 627,429 and 599,075 common shares were not included in the computation of diluted loss per share applicable to common stockholders as they are anti-dilutive as a result of net losses for the periods ended September 30, 2013 and September 30, 2012, respectively. | ||||||||
Preferred Stock | ||||||||
A summary of the Company’s preferred stock is as follows: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
Shares Issued & | Shares Issued & | |||||||
Offering | Outstanding | Outstanding | ||||||
(unaudited) | ||||||||
Series A convertible | 47,250 | 47,250 | ||||||
Series B convertible, 10% cumulative dividend | 93,750 | 93,750 | ||||||
Series C convertible, 10% cumulative dividend | 38,333 | 38,333 | ||||||
Series D convertible, 10% cumulative dividend | 175,000 | 175,000 | ||||||
Series E convertible, 10% cumulative dividend | 19,022 | 19,022 | ||||||
Total Preferred Stock | 373,355 | 373,355 | ||||||
As of September 30, 2013 and 2012, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation. | ||||||||
Summary of Preferred Stock Terms | ||||||||
Series A Convertible Preferred Stock | ||||||||
Liquidation Value: | $4.50 per share, $212,625 | |||||||
Conversion Price: | $103.034 per share | |||||||
Conversion Rate: | 0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034) | |||||||
Voting Rights: | None | |||||||
Dividends: | None | |||||||
Conversion Period: | Any time | |||||||
Series B Convertible Preferred Stock | ||||||||
Liquidation Value: | $4.00 per share, $375,000 | |||||||
Conversion Price: | $10.00 per share | |||||||
Conversion Rate: | 0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing March 31, 2001 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $473,000 | ||||||||
Series C Convertible Preferred Stock | ||||||||
Liquidation Value: | $3.00 per share, $115,000 | |||||||
Conversion Price: | $6.00 per share | |||||||
Conversion Rate: | 0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing March 31, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $137,000 | ||||||||
Series D Convertible Preferred Stock | ||||||||
Liquidation Value: | $10.00 per share, $1,750,000 | |||||||
Conversion Price: | $10.00 per share | |||||||
Conversion Rate: | 1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing April 30, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $2,086,000 | ||||||||
Series E Convertible Preferred Stock | ||||||||
Liquidation Value: | $22.00 per share, $418,488 | |||||||
Conversion Price: | $8.00 per share | |||||||
Conversion Rate: | 2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00) | |||||||
Voting Rights: | Equal in all respects to holders of common shares | |||||||
Dividends: | 10%—Quarterly—Commencing May 31, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $501,000 | ||||||||
Issuance of Common Stock for Cash | ||||||||
During the quarter ended September 30, 2013, the Company agreed to issue 12,500,000 shares of restricted, unregistered common stock to qualified investors for $250,000, or $0.02 per share. These shares have not yet been issued. | ||||||||
For the nine months ended September 30, 2013, the Company agreed to issue an aggregate of 14,000,000 shares of restricted, unregistered common stock to qualified investors for $280,000, or $0.02 per share. These shares have not yet been issued. | ||||||||
Issuance of Common Stock as Payment for Services | ||||||||
During the nine months ended September 30, 2013, the Company issued to two of the Company’s directors, Mauro Scimia (“Scimia”) and Xavier Carbonell (“Carbonell”), 902,764 and 1,805,528 shares of restricted, unregistered common stock, respectively, for consulting services rendered, and the Company recorded a charge of $52,500, or $0.02 per share, as a selling, general and administrative expense. | ||||||||
The Company during the nine months ended September 30, 2013, also issued 2,346,148 shares of restricted, unregistered common stock to a consultant for services rendered, and recorded $36,000 as a selling, general and administrative expense. | ||||||||
During the nine months ended September 30, 2013, the Company reversed $48,000 of consulting compensation expense from a consulting agreement issued several years ago. The consultant never completed any of the tasks required under the contract and therefore did not meet the requirements to vest any of the 2,055,527 shares granted, but never issued, under the contract. The $48,000 was a reduction in selling, general & administrative expense. | ||||||||
Issuance of Common Stock as Settlement of Debt | ||||||||
During the nine months ended September 30, 2013, Robert McCullough, our Chief Executive Officer and Chief Financial Officer, converted $3,250,000 of debt owed to him into 162,500,000 shares of restricted, unregistered common stock at a price of $0.02 per share. As a result of this transaction, Mr. McCullough beneficially owns 167,690,706 shares of common stock which is 62.22% of our outstanding common stock. | ||||||||
Also during the nine months ended September 30, 2013, the Company issued to two current independent directors, Alexander Milley and Dr. John Abeles, an aggregate 7,500,000 shares of restricted, unregistered common stock, respectively, for past directors fees totaling $150,000, or $0.02 per share. In addition, the Company recorded the payment of $50,000 for services rendered to a former director in the form of 2,500,000 shares of restricted, unregistered common stock valued at $0.02 per share. These shares have not yet been issued. | ||||||||
The shares issued to the Company’s CEO and members of the board of directors in the debt settlements described above were issued at a price higher than the trading price of the common stock the day the Board authorized the settlement. The Company has not treated the transaction as a troubled debt restructuring nor as an extinguishment of the debt, but as essentially a recapitalization of the Company, and therefore no gain or loss has been recorded on the difference in the fair value of the stock as it traded to the amount used to settle the debt. | ||||||||
Issuance of Common Stock as Payment for Employee Compensation | ||||||||
During the nine months ended September 30, 2013, the Company issued to Augusto Ocana (“Ocana”), a director and vice president of the Company, 1,805,528 shares of restricted, unregistered common stock, for services rendered. The Company recorded a charge of $35,000, or $0.02 per share, as a selling, general and administrative expense. | ||||||||
Our officers and directors own an aggregate 198,199,145 shares of common stock which is 73.53% of our outstanding common stock. | ||||||||
Commitments_and_contingencies
Commitments and contingencies | 9 Months Ended |
Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and contingencies | ' |
Note 7. Commitments and Contingencies | |
Legal Proceedings | |
There are no pending legal proceedings against the Company. To the Company’s knowledge, there have been no cases initiated by or against the Company, nor any cases resolved, since the date of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 was filed with the SEC. | |
The Company has been a party to a number of other proceedings, informal demands, or debt for services brought by former unsecured creditors to collect past due amounts for services. The Company is attempting to settle these demands and unfilled claims. The Company does not consider any of these claims to be material. | |
During the nine months ended September 30, 2013, the Company recorded a write off totaling $374,000 of trade debt deemed uncollectible by the holder due to the expiration of the statute of limitations and $149,000 as a result of the liquidation of its subsidiaries. These transactions were recorded as a reduction of selling, general and administration expense. | |
Contingencies | |
The Company has not filed its Illinois franchise returns for 2012, 2011, 2010 and 2009 or paid its franchise tax for those years. During the second quarter the Company filed and paid its franchise taxes for 2009 and 2010 for Delaware. The Company determined that it had over accrued for those periods by approximately $44,000, which was reversed and is shown as a reduction in selling, general & administrative expenses. The Company believes that it has made adequate provision for the liability including penalties and interest. | |
Fixed_Assets_Tables
Fixed Assets (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property and equipment estimated useful lives | ' | |||||||
Fixed assets consist of the following: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Furniture and fixtures | $ | 40 | $ | 47 | ||||
Laboratory equipment | 508 | 508 | ||||||
Computer and communications equipment | 261 | 261 | ||||||
Design and tooling | 1,204 | 1,204 | ||||||
2,013 | 2,020 | |||||||
Less accumulated depreciation and amortization | -1,996 | -1,941 | ||||||
Total | $ | 17 | $ | 79 | ||||
Accrued_Expenses_Tables
Accrued Expenses (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Accrued Expenses | ' | |||||||
Accrued expenses include the following: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Accrued interest | $ | 29 | $ | 65 | ||||
Accrued franchise and other taxes | 301 | 484 | ||||||
Accrued compensation | 20 | 190 | ||||||
Other accrued expenses | 150 | 164 | ||||||
Total | $ | 500 | $ | 903 | ||||
Notes_Payable_and_Advancesrela1
Notes Payable and Advances-related parties (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Notes Payable to Unrelated Parties | ' | |||||||
Notes payable to unrelated parties consist of: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
(Unaudited) | ||||||||
Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate | 15 | 15 | ||||||
9% per annum, due December 20, 2001. | ||||||||
Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; | 21 | 21 | ||||||
due December 31, 2003; interest rate 8% per annum payable | ||||||||
after December 31, 2003 | ||||||||
Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; | — | 34 | ||||||
Interest rate Canadian Prime plus 6% per annum, due December 27, 1999; | ||||||||
represents a debt of AccuMed | ||||||||
$ | 36 | $ | 70 | |||||
Stockholders_Equity_Deficit_Ta
Stockholders' Equity (Deficit) (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Stockholders' Equity (Deficit) [Abstract] | ' | |||||||
Schedule of Calculation of Numerator and Denominator in Earnings Per Share | ' | |||||||
A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows: | ||||||||
September 30, | September 30, | |||||||
2013 | 2012 | |||||||
(unaudited) | ||||||||
Basic and Diluted: | ||||||||
Net loss applicable to common stockholder (in thousands) | $ | -715 | $ | -1,208 | ||||
Weighted average common shares outstanding | 172,711,623 | 70,278,553 | ||||||
Net loss per common share | $ | 0 | $ | -0.02 | ||||
Summary of Company's Preferred Stock | ' | |||||||
A summary of the Company’s preferred stock is as follows: | ||||||||
September 30, | December 31, | |||||||
2013 | 2012 | |||||||
Shares Issued & | Shares Issued & | |||||||
Offering | Outstanding | Outstanding | ||||||
(unaudited) | ||||||||
Series A convertible | 47,250 | 47,250 | ||||||
Series B convertible, 10% cumulative dividend | 93,750 | 93,750 | ||||||
Series C convertible, 10% cumulative dividend | 38,333 | 38,333 | ||||||
Series D convertible, 10% cumulative dividend | 175,000 | 175,000 | ||||||
Series E convertible, 10% cumulative dividend | 19,022 | 19,022 | ||||||
Total Preferred Stock | 373,355 | 373,355 | ||||||
Summary of Preferred Stock Terms | ' | |||||||
As of September 30, 2013 and 2012, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation. | ||||||||
Summary of Preferred Stock Terms | ||||||||
Series A Convertible Preferred Stock | ||||||||
Liquidation Value: | $4.50 per share, $212,625 | |||||||
Conversion Price: | $103.034 per share | |||||||
Conversion Rate: | 0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034) | |||||||
Voting Rights: | None | |||||||
Dividends: | None | |||||||
Conversion Period: | Any time | |||||||
Series B Convertible Preferred Stock | ||||||||
Liquidation Value: | $4.00 per share, $375,000 | |||||||
Conversion Price: | $10.00 per share | |||||||
Conversion Rate: | 0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing March 31, 2001 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $473,000 | ||||||||
Series C Convertible Preferred Stock | ||||||||
Liquidation Value: | $3.00 per share, $115,000 | |||||||
Conversion Price: | $6.00 per share | |||||||
Conversion Rate: | 0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing March 31, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $137,000 | ||||||||
Series D Convertible Preferred Stock | ||||||||
Liquidation Value: | $10.00 per share, $1,750,000 | |||||||
Conversion Price: | $10.00 per share | |||||||
Conversion Rate: | 1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00) | |||||||
Voting Rights: | None | |||||||
Dividends: | 10%—Quarterly—Commencing April 30, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $2,086,000 | ||||||||
Series E Convertible Preferred Stock | ||||||||
Liquidation Value: | $22.00 per share, $418,488 | |||||||
Conversion Price: | $8.00 per share | |||||||
Conversion Rate: | 2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00) | |||||||
Voting Rights: | Equal in all respects to holders of common shares | |||||||
Dividends: | 10%—Quarterly—Commencing May 31, 2002 | |||||||
Conversion Period: | Any time | |||||||
Cumulative and undeclared dividends in arrears at September 30, 2013 were $501,000 | ||||||||
Organization_Additional_Inform
Organization - Additional Information (Detail) (USD $) | 9 Months Ended | ||||
Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2011 | ||
Cash and cash equivalents | $11,000 | $0 | $39,000 | [1] | $14,000 |
Debt Conversion, Converted Instrument, Amount | 3,250,000 | 0 | ' | ' | |
Gain Loss On Liquidations Of Subsidiary | -149,000 | 0 | ' | ' | |
Robert McCullough [Member] | ' | ' | ' | ' | |
Debt Conversion, Converted Instrument, Amount | $3,250,000 | ' | ' | ' | |
Debt Conversion, Converted Instrument, Shares Issued | 162,500,000 | ' | ' | ' | |
Share Price | $0.02 | ' | ' | ' | |
Equity Method Investment Ownership Number Of Shares Held | 167,690,706 | ' | ' | ' | |
Equity Method Investment, Ownership Percentage | 62.22% | ' | ' | ' | |
Officers and Directors [Member] | ' | ' | ' | ' | |
Equity Method Investment Ownership Number Of Shares Held | 198,199,145 | ' | ' | ' | |
Equity Method Investment, Ownership Percentage | 73.53% | ' | ' | ' | |
[1] | Derived from audited information |
Fixed_Assets_Detail
Fixed Assets (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
In Thousands, unless otherwise specified | |||
Property, Plant and Equipment [Line Items] | ' | ' | |
Furniture and fixtures | $40 | $47 | |
Laboratory equipment | 508 | 508 | |
Computer and communications equipment | 261 | 261 | |
Design and tooling | 1,204 | 1,204 | |
Property, Plant and Equipment, Gross, Total | 2,013 | 2,020 | |
Less accumulated depreciation and amortization | -1,996 | -1,941 | |
Total | $17 | $79 | [1] |
[1] | Derived from audited information |
Fixed_Assets_Additional_Inform
Fixed Assets - Additional Information (Detail) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Property, Plant and Equipment [Line Items] | ' | ' |
Depreciation expense | $62,000 | $171,000 |
Accrued_Expenses_Detail
Accrued Expenses (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
In Thousands, unless otherwise specified | |||
Accrued Liabilities [Line Items] | ' | ' | |
Accrued interest | $29 | $65 | |
Accrued franchise and other taxes | 301 | 484 | |
Accrued compensation | 20 | 190 | |
Other accrued expenses | 150 | 164 | |
Total | $500 | $903 | [1] |
[1] | Derived from audited information |
Notes_Payable_and_Advancesrela2
Notes Payable and Advances-related parties (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | |
In Thousands, unless otherwise specified | |||
Debt Instrument [Line Items] | ' | ' | |
Notes payable | $36 | $70 | [1] |
Robert Shaw [Member] | ' | ' | |
Debt Instrument [Line Items] | ' | ' | |
Notes payable | 15 | 15 | |
Ventana Medical Systems, Inc [Member] | ' | ' | |
Debt Instrument [Line Items] | ' | ' | |
Notes payable | 21 | 21 | |
Xillix Technologies Corporation [Member] | ' | ' | |
Debt Instrument [Line Items] | ' | ' | |
Notes payable | $0 | $34 | |
[1] | Derived from audited information |
Notes_Payable_and_Advancesrela3
Notes Payable and Advances-related parties (Parenthetical) (Detail) (USD $) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Dec. 31, 2012 | |
Debt Instrument [Line Items] | ' | ' |
Promissory note, interest rate | 8.00% | ' |
Robert Shaw [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Promissory note | $25,000 | $25,000 |
Promissory note, date of issue | 20-Sep-01 | 20-Sep-01 |
Promissory note, interest rate | 9.00% | 9.00% |
Promissory note, due date | 20-Dec-01 | 20-Dec-01 |
Ventana Medical Systems, Inc [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Promissory note | 62,946 | 62,946 |
Promissory note, date of issue | 30-Nov-03 | 30-Nov-03 |
Promissory note, interest rate | 8.00% | 8.00% |
Promissory note, due date | 31-Dec-03 | 31-Dec-03 |
Xillix Technologies Corporation [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Promissory note | $361,000 | $361,000 |
Promissory note, date of issue | 26-Jun-98 | 26-Jun-98 |
Promissory note, interest rate | 6.00% | 6.00% |
Promissory note, due date | 27-Dec-99 | 27-Dec-99 |
Notes_Payable_and_Advancesrela4
Notes Payable and Advances-related parties - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Advance from related party | ' | ' | $145,000 | $524,000 |
Annual interest rate | ' | ' | 8.00% | ' |
Non-cash interest expense | 2,000 | 59,000 | 96,000 | 170,000 |
Xillex Technologies Corporation [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Notes Payable And Accrued Interest | ' | ' | $73,000 | ' |
Stockholders_Equity_Deficit_Re
Stockholders' Equity (Deficit) (Reconciliation of Numerator and Denominator Used in Calculation of Loss Per Share) (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Basic and Diluted: | ' | ' | ' | ' |
Net loss applicable to common stockholder | ($402) | ($53) | ($715) | ($1,208) |
Weighted average common shares outstanding | 268,389,553 | 72,964,624 | 172,711,623 | 70,278,553 |
Net loss per common share | $0 | $0 | $0 | ($0.02) |
Stockholders_Equity_Deficit_Su
Stockholders' Equity (Deficit) (Summary of Preferred Stock) (Detail) | Sep. 30, 2013 | Dec. 31, 2012 | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 373,355 | 373,355 | [1] |
Preferred stock, shares outstanding | 373,355 | 373,355 | [1] |
Series A Convertible Preferred Stock [Member] | ' | ' | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 47,250 | 47,250 | |
Preferred stock, shares outstanding | 47,250 | 47,250 | |
Series B Convertible Preferred Stock [Member] | ' | ' | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 93,750 | 93,750 | |
Preferred stock, shares outstanding | 93,750 | 93,750 | |
Series C Convertible Preferred Stock [Member] | ' | ' | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 38,333 | 38,333 | |
Preferred stock, shares outstanding | 38,333 | 38,333 | |
Series D Convertible Preferred Stock [Member] | ' | ' | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 175,000 | 175,000 | |
Preferred stock, shares outstanding | 175,000 | 175,000 | |
Series E Convertible Preferred Stock [Member] | ' | ' | |
Class of Stock [Line Items] | ' | ' | |
Preferred stock, shares issued | 19,022 | 19,022 | |
Preferred stock, shares outstanding | 19,022 | 19,022 | |
[1] | Derived from audited information |
Stockholders_Equity_Deficit_Su1
Stockholders' Equity (Deficit) (Summary of Preferred Stock) (Parenthetical) (Detail) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Dec. 31, 2012 | |
Series B Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Convertible preferred stock, cumulative dividend rate | 10.00% | 10.00% |
Series C Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Convertible preferred stock, cumulative dividend rate | 10.00% | 10.00% |
Series D Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Convertible preferred stock, cumulative dividend rate | 10.00% | 10.00% |
Series E Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Convertible preferred stock, cumulative dividend rate | 10.00% | 10.00% |
Stockholders_Equity_Deficit_Su2
Stockholders' Equity (Deficit) (Summary of Preferred Stock Terms) (Detail) (USD $) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Dec. 31, 2012 | |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | $2,871 | ' |
Series A Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | 212,625 | ' |
Preferred stock, conversion Price | $103.03 | ' |
Preferred stock, conversion Rate | 0.04% | ' |
Preferred stock, voting Rights | 'None | ' |
Preferred stock, dividends | 0.00% | ' |
Preferred stock, conversion Period | 'Any time | ' |
Series B Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | 375,000 | ' |
Preferred stock, conversion Price | $10 | ' |
Preferred stock, conversion Rate | 0.40% | ' |
Preferred stock, voting Rights | 'None | ' |
Preferred stock, dividends | 10.00% | 10.00% |
Preferred stock, conversion Period | 'Any time | ' |
Preferred stock, cumulative and undeclared dividends in arrears | 473,000 | ' |
Series C Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | 115,000 | ' |
Preferred stock, conversion Price | $6 | ' |
Preferred stock, conversion Rate | 0.50% | ' |
Preferred stock, voting Rights | 'None | ' |
Preferred stock, dividends | 10.00% | 10.00% |
Preferred stock, conversion Period | 'Any time | ' |
Preferred stock, cumulative and undeclared dividends in arrears | 137,000 | ' |
Series D Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | 1,750,000 | ' |
Preferred stock, conversion Price | $10 | ' |
Preferred stock, conversion Rate | 1.00% | ' |
Preferred stock, voting Rights | 'None | ' |
Preferred stock, dividends | 10.00% | 10.00% |
Preferred stock, conversion Period | 'Any time | ' |
Preferred stock, cumulative and undeclared dividends in arrears | 2,086,000 | ' |
Series E Convertible Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock, Liquidation value | 418,488 | ' |
Preferred stock, conversion Price | $8 | ' |
Preferred stock, conversion Rate | 2.75% | ' |
Preferred stock, voting Rights | 'Equal in all respects to holders of common shares | ' |
Preferred stock, dividends | 10.00% | 10.00% |
Preferred stock, conversion Period | 'Any time | ' |
Preferred stock, cumulative and undeclared dividends in arrears | $501,000 | ' |
Stockholders_Equity_Deficit_Su3
Stockholders' Equity (Deficit) (Summary of Preferred Stock Terms) (Parenthetical) (Detail) (USD $) | 9 Months Ended |
Sep. 30, 2013 | |
Series A Convertible Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Preferred stock, liquidation Value per share | $4.50 |
Series B Convertible Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Preferred stock, liquidation Value per share | $4 |
Preferred stock, frequency of dividend payment | '10%—Quarterly—Commencing March 31, 2001 |
Preferred stock, dividend date of commencement | 31-Mar-01 |
Series C Convertible Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Preferred stock, liquidation Value per share | $3 |
Preferred stock, frequency of dividend payment | '10%QuarterlyCommencing March 31, 2002 |
Preferred stock, dividend date of commencement | 31-Mar-02 |
Series D Convertible Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Preferred stock, liquidation Value per share | $10 |
Preferred stock, frequency of dividend payment | '10%—Quarterly—Commencing April 30, 2002 |
Preferred stock, dividend date of commencement | 30-Apr-02 |
Series E Convertible Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Preferred stock, liquidation Value per share | $22 |
Preferred stock, frequency of dividend payment | '10%QuarterlyCommencing May 31, 2002 |
Preferred stock, dividend date of commencement | 31-May-02 |
Stockholders_Equity_Deficit_Ad
Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $) | 9 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | |||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Consulting Compensation Expense [Member] | Robert McCullough [Member] | Alexander Milley and Dr. John Abeles [Member] | Former Director [Member] | Ocana [Member] | Officers and Directors [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Warrants and Stock Options [Member] | Warrants and Stock Options [Member] | Preferred Stock | Preferred Stock | |||
Qualified Investor [Member] | Qualified Investor [Member] | Scimia [Member] | Carbonell [Member] | Former Director [Member] | ||||||||||||||
Stockholders Equity Note [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Anti-dilutive securities not included in the computation of diluted loss per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 705,667 | 922,667 | 627,429 | 599,075 |
Common Stock, Shares, Issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,500,000 | 14,000,000 | ' | ' | ' | ' | ' | ' | ' |
Common Stock Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | $250,000 | $280,000 | ' | ' | ' | ' | ' | ' | ' |
Share Price | ' | ' | ' | $0.02 | $0.02 | ' | ' | ' | ' | $0.02 | $0.02 | ' | ' | $0.02 | ' | ' | ' | ' |
Stock Issued During Period, Shares, Issued for Services | 2,346,148 | ' | ' | ' | 7,500,000 | ' | 1,805,528 | ' | ' | ' | ' | 902,764 | 1,805,528 | ' | ' | ' | ' | ' |
Stock Issued During Period, Value, Issued for Services | 200,000 | 0 | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Compensation expense | ' | ' | 48,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Vesting shares number | ' | ' | 2,055,527 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Selling General And Administrative Expense Recorded Value | 36,000 | ' | 48,000 | ' | ' | ' | 35,000 | ' | 52,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Selling General And Administrative Expense Recorded Per Share | ' | ' | ' | ' | ' | ' | $0.02 | ' | $0.02 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Conversion, Converted Instrument, Amount | 3,250,000 | 0 | ' | 3,250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Conversion, Converted Instrument, Shares Issued | ' | ' | ' | 162,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity Method Investment Ownership Number Of Shares Held | ' | ' | ' | 167,690,706 | ' | ' | ' | 198,199,145 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity Method Investment, Ownership Percentage | ' | ' | ' | 62.22% | ' | ' | ' | 73.53% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Record Of Payment For Services Rendered | ' | ' | ' | ' | ' | $50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Capital Shares Reserved for Future Issuance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,500,000 | ' | ' | ' | ' |
Commitments_and_contingencies_
Commitments and contingencies - Additional Information (Detail) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Commitments and Contingencies Disclosure [Line Items] | ' | ' |
Gain Loss On Liquidations Of Subsidiary | $149,000 | $0 |
Selling, General and Administrative Expenses [Member] | ' | ' |
Commitments and Contingencies Disclosure [Line Items] | ' | ' |
Settlement of trade debt | 374,000 | ' |
Adjustment of an accrual based upon actual reduced liability | $44,000 | ' |